<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00614120</url>
  </required_header>
  <id_info>
    <org_study_id>NN2211-1796</org_study_id>
    <nct_id>NCT00614120</nct_id>
  </id_info>
  <brief_title>Effect of Liraglutide or Glimepiride Added to Metformin on Blood Glucose Control in Subjects With Type 2 Diabetes</brief_title>
  <official_title>Effect of Liraglutide or Glimepiride Added to Metformin on Glycaemic Control in Subjects With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is conducted in Asia. The trial is designed to compare the effect on glycaemic
      control of liraglutide or glimepiride added to metformin in subjects with type 2 diabetes
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Glycosylated Haemoglobin A1c (HbA1c)</measure>
    <time_frame>week 0, week 16</time_frame>
    <description>Percentage point change in Glycosylated Haemoglobin A1c (HbA1c) from baseline (week 0) to 16 weeks (end of treatment).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Body Weight</measure>
    <time_frame>week 0, week 16</time_frame>
    <description>Change in body weight from baseline (week 0) to 16 weeks (end of treatment)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Self-measured Fasting Plasma Glucose</measure>
    <time_frame>week 0, week 16</time_frame>
    <description>Change in self-measured fasting plasma glucose from baseline (week 0) to 16 weeks (end of treatment). Self-measurement of plasma glucose was performed using a glucose meter and subjects were instructed to record self-measured plasma glucose values into a diary.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>7-point Self-measured Plasma Glucose Profiles</measure>
    <time_frame>week 0, 8, 12 and 16</time_frame>
    <description>Summary of 7-Point Profiles of Self-Measured Plasma Glucose by Treatment, Week and Time. The 7 time points for self-measurements for all treatment groups were: Before each meal (breakfast, lunch and dinner), at 90 min after start of each meal (breakfast, lunch and dinner) and at bedtime, measured over 16 weeks of treatment (at week 0, 8, 12 and 16).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Beta-cell Function</measure>
    <time_frame>week 0, week 16</time_frame>
    <description>Change in beta cell function from baseline (week 0) to 16 weeks (end of treatment). Beta-cell function was derived from fasting plasma glucose (FPG) and fasting insulin concentrations using the homeostasic model assessment (HOMA) method which uses the assumption that normal-weight normal subjects aged under 35 years have a 100% beta-cell function (HOMA-B).
Beta-cell function: HOMA-B (%) = 20∙fasting insulin[uU/mL] divided by (FPG mmol/L]‑3.5).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fasting Lipid Profile</measure>
    <time_frame>week 0, week 16</time_frame>
    <description>Change in fasting lipid profiles from baseline (week 0) to 16 weeks (end of treatment). Fasting lipid profiles is based on:
Total Cholesterol (TC)
Low-density Lipoprotein-cholesterol (LDL-C)
Very Low-density Lipoprotein-cholesterol (VLDL-C)
High-density Lipoprotein-cholesterol (HDL-C)
Triglyceride (TG)
Free Fatty Acid (FFA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fasting Lipid Profile, APO-B</measure>
    <time_frame>week 0, week 16</time_frame>
    <description>Change in fasting lipid profiles based on apolipoprotein B (Apo-B) from baseline (week 0) to 16 weeks (end of treatment).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypoglycaemic Episodes</measure>
    <time_frame>weeks 0-16</time_frame>
    <description>Total number of hypoglycaemic episodes over 16 weeks of treatment occurring from baseline (week 0) to end of treatment (week 16). Hypoglycaemic episodes were defined as major, minor, or symptoms only. Major if the subject was unable to treat her/himself. Minor if subject was able to treat her/himself and plasma glucose was below 3.1 mmol/L. Symptoms only if subject was able to treat her/himself and with no plasma glucose measurement or plasma glucose higher than or equal to 3.1 mmol/L.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">929</enrollment>
  <condition>Diabetes</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Lira 0.6 + Met</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Liraglutide 0.6 mg + metformin + glimepiride placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lira 1.2 + Met</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Liraglutide 1.2 mg + metformin + glimepiride placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lira 1.8 + Met</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Liraglutide + metformin + glimepiride placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glim + Met</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Glimepiride 4.0 mg + metformin + liraglutide placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>liraglutide</intervention_name>
    <description>0.6 mg/day, s.c. (under the skin) injection</description>
    <arm_group_label>Lira 0.6 + Met</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Glimepiride placebo, capsules</description>
    <arm_group_label>Lira 0.6 + Met</arm_group_label>
    <arm_group_label>Lira 1.2 + Met</arm_group_label>
    <arm_group_label>Lira 1.8 + Met</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>liraglutide</intervention_name>
    <description>1.2 mg/day, s.c. (under the skin) injection</description>
    <arm_group_label>Lira 1.2 + Met</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>liraglutide</intervention_name>
    <description>1.8 mg/day, s.c. (under the skin) injection</description>
    <arm_group_label>Lira 1.8 + Met</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>glimepiride</intervention_name>
    <description>Capsules, 4.0 mg/day</description>
    <arm_group_label>Glim + Met</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>metformin</intervention_name>
    <description>Tablets, 1.5-2.0 g/day</description>
    <arm_group_label>Lira 0.6 + Met</arm_group_label>
    <arm_group_label>Lira 1.2 + Met</arm_group_label>
    <arm_group_label>Lira 1.8 + Met</arm_group_label>
    <arm_group_label>Glim + Met</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Liraglutide placebo, s.c. (under the skin) injection</description>
    <arm_group_label>Glim + Met</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 diabetes

          -  Subjects diagnosed with type 2 diabetes and treated with one or more oral antidiabetic
             drugs (OADs) for the last 3 months

          -  HbA1c: 7.0-11.0% (both incl.) for subjects on OAD alone

          -  HbA1c: 7.0-10.0 % (both incl.) for subjects on OAD combination therapy

          -  BMI less than 45.0 kg/m^2

        Exclusion Criteria:

          -  Treatment with insulin within the last 3 months prior to the trial

          -  Impaired liver or/and renal function

          -  Significant cardiovascular disease over the last 6 months

          -  Known retinopathy or maculopathy

          -  Recurrent major hypoglycaemia or hypoglycaemic unawareness
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Registry (GCR, 1452), MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100029</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400010</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <zip>350025</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <zip>150001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <zip>150086</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430022</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210008</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <zip>215004</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Wuxi</city>
        <state>Jiangsu</state>
        <zip>214023</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200003</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310003</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Shenyang</city>
        <zip>110001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Tianjin</city>
        <zip>300052</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Wuhan</city>
        <zip>430060</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Hyderabad</city>
        <state>Andhra Pradesh</state>
        <zip>500 001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Hyderbad</city>
        <state>Andhra Pradesh</state>
        <zip>500 012</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Ahmedabad</city>
        <state>Gujarat</state>
        <zip>380 015</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560 017</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Cochin</city>
        <state>Kerala</state>
        <zip>695010</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Mumbai</city>
        <state>Maharashtra</state>
        <zip>400010</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <zip>411 037</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>New Dehli</city>
        <state>New Delhi</state>
        <zip>110029</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Bhubaneswar</city>
        <state>Orissa</state>
        <zip>751019</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Jaipur</city>
        <state>Rajasthan</state>
        <zip>302006</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Chennai</city>
        <state>Tamil Nadu</state>
        <zip>600 013</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Madurai</city>
        <state>Tamil Nadu</state>
        <zip>625 020</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Kolkata</city>
        <state>West Bengal</state>
        <zip>700054</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Cochin</city>
        <zip>682 304</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Ghaziabad</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Kolkata</city>
        <zip>700017</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Kolkata</city>
        <zip>700026</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Mumbai</city>
        <zip>400 0067</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Mumbai</city>
        <zip>400016</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>New Delhi</city>
        <zip>110017</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Patna</city>
        <zip>800020</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Secunderabad</city>
        <zip>500 003</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Trivandrum</city>
        <zip>695029</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Visakhapatnam</city>
        <zip>530002</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Goyang</city>
        <zip>410-719</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Incheon</city>
        <zip>405-220</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>08308</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>130-872</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>137-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>150-713</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Sungnam</city>
        <zip>463-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Suwon</city>
        <zip>16499</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
    <country>India</country>
    <country>Korea, Republic of</country>
  </location_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <results_reference>
    <citation>Yang W, Chen L, Ji Q, Liu X, Ma J, Tandon N, Bhattacharyya A, Kumar A, Kim KW, Yoon KH, Bech OM, Zychma M. Liraglutide provides similar glycaemic control as glimepiride (both in combination with metformin) and reduces body weight and systolic blood pressure in Asian population with type 2 diabetes from China, South Korea and India: a 16-week, randomized, double-blind, active control trial(*). Diabetes Obes Metab. 2011 Jan;13(1):81-8. doi: 10.1111/j.1463-1326.2010.01323.x.</citation>
    <PMID>21114607</PMID>
  </results_reference>
  <results_reference>
    <citation>Alves C, Batel-Marques F, Macedo AF. A meta-analysis of serious adverse events reported with exenatide and liraglutide: acute pancreatitis and cancer. Diabetes Res Clin Pract. 2012 Nov;98(2):271-84. doi: 10.1016/j.diabres.2012.09.008. Epub 2012 Sep 23.</citation>
    <PMID>23010561</PMID>
  </results_reference>
  <results_reference>
    <citation>Jensen TM, Saha K, Steinberg WM. Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials. Diabetes Care. 2015 Jun;38(6):1058-66. doi: 10.2337/dc13-1210. Epub 2014 Dec 12. Review. Erratum in: Diabetes Care. 2015 Aug;38(8):1622.</citation>
    <PMID>25504028</PMID>
  </results_reference>
  <results_reference>
    <citation>Ingwersen SH, Petri KC, Tandon N, Yoon KH, Chen L, Vora J, Yang W. Liraglutide pharmacokinetics and dose-exposure response in Asian subjects with Type 2 diabetes from China, India and South Korea. Diabetes Res Clin Pract. 2015 Apr;108(1):113-9. doi: 10.1016/j.diabres.2015.01.001. Epub 2015 Jan 19.</citation>
    <PMID>25684604</PMID>
  </results_reference>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 15, 2008</study_first_submitted>
  <study_first_submitted_qc>February 12, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 13, 2008</study_first_posted>
  <results_first_submitted>February 23, 2010</results_first_submitted>
  <results_first_submitted_qc>February 23, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 12, 2010</results_first_posted>
  <disposition_first_submitted>November 9, 2009</disposition_first_submitted>
  <disposition_first_submitted_qc>November 9, 2009</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">November 11, 2009</disposition_first_posted>
  <last_update_submitted>January 25, 2017</last_update_submitted>
  <last_update_submitted_qc>January 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glimepiride</mesh_term>
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Liraglutide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 51 centres in three countries: China (17), India (24) and South Korea (10)</recruitment_details>
      <pre_assignment_details>A metformin run-in period of 3 weeks followed by a metformin maintenance period of 3 weeks before randomisation with dose levels increased to 2000 mg/day. Subjects already on metformin therapy at enrolment could go through a modified titration period or advance directly to the metformin maintenance period at the discretion of the investigator.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Lira 0.6 + Met</title>
          <description>Liraglutide 0.6 mg once daily + metformin 1.5-2.0 g daily + glimepiride placebo</description>
        </group>
        <group group_id="P2">
          <title>Lira 1.2 + Met</title>
          <description>Liraglutide 1.2 mg once daily + metformin 1.5-2.0 g daily + glimepiride placebo</description>
        </group>
        <group group_id="P3">
          <title>Lira 1.8 + Met</title>
          <description>Liraglutide 1.8 mg once daily + metformin 1.5-2.0 g daily + glimepiride placebo</description>
        </group>
        <group group_id="P4">
          <title>Glim + Met</title>
          <description>Glimepiride 4.0 mg + metformin 1.5-2.0 g daily + liraglutide placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="231">Randomised</participants>
                <participants group_id="P2" count="233">Randomised</participants>
                <participants group_id="P3" count="234">Randomised</participants>
                <participants group_id="P4" count="231">Randomised</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Exposed to Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="231"/>
                <participants group_id="P2" count="233"/>
                <participants group_id="P3" count="233">Subject withdrew before exposure to study products, and thus not included in full analysis set.</participants>
                <participants group_id="P4" count="231"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="202"/>
                <participants group_id="P2" count="187"/>
                <participants group_id="P3" count="175"/>
                <participants group_id="P4" count="215"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="46"/>
                <participants group_id="P3" count="59"/>
                <participants group_id="P4" count="16"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="30"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal criteria</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="16"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did not meet trial criteria</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>hCG positive (not pregnant)</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Hypoglycaemia</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of trial product</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Late syphilis, latent</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Taken inhibition medication eg Prandin</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Lira 0.6 + Met</title>
          <description>Liraglutide 0.6 mg once daily + metformin 1.5-2.0 g daily + glimepiride placebo</description>
        </group>
        <group group_id="B2">
          <title>Lira 1.2 + Met</title>
          <description>Liraglutide 1.2 mg once daily + metformin 1.5-2.0 g daily + glimepiride placebo</description>
        </group>
        <group group_id="B3">
          <title>Lira 1.8 + Met</title>
          <description>Liraglutide 1.8 mg once daily + metformin 1.5-2.0 g daily + glimepiride placebo</description>
        </group>
        <group group_id="B4">
          <title>Glim + Met</title>
          <description>Glimepiride 4.0 mg + metformin 1.5-2.0 g daily + liraglutide placebo</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="231"/>
            <count group_id="B2" value="233"/>
            <count group_id="B3" value="234"/>
            <count group_id="B4" value="231"/>
            <count group_id="B5" value="929"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.5" spread="9.5"/>
                    <measurement group_id="B2" value="53.5" spread="9.6"/>
                    <measurement group_id="B3" value="52.7" spread="9.1"/>
                    <measurement group_id="B4" value="53.6" spread="9.7"/>
                    <measurement group_id="B5" value="53.3" spread="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="106"/>
                    <measurement group_id="B2" value="105"/>
                    <measurement group_id="B3" value="108"/>
                    <measurement group_id="B4" value="96"/>
                    <measurement group_id="B5" value="415"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="125"/>
                    <measurement group_id="B2" value="128"/>
                    <measurement group_id="B3" value="126"/>
                    <measurement group_id="B4" value="135"/>
                    <measurement group_id="B5" value="514"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Previous OAD treatment</title>
          <description>OAD = Oral Anti-Diabetic Drug</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Mono-therapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72"/>
                    <measurement group_id="B2" value="74"/>
                    <measurement group_id="B3" value="75"/>
                    <measurement group_id="B4" value="68"/>
                    <measurement group_id="B5" value="289"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Combination therapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="159"/>
                    <measurement group_id="B2" value="159"/>
                    <measurement group_id="B3" value="159"/>
                    <measurement group_id="B4" value="163"/>
                    <measurement group_id="B5" value="640"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <description>Body Mass Index</description>
          <units>kg/m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.9" spread="4.2"/>
                    <measurement group_id="B2" value="25.4" spread="3.7"/>
                    <measurement group_id="B3" value="25.8" spread="3.8"/>
                    <measurement group_id="B4" value="25.3" spread="3.7"/>
                    <measurement group_id="B5" value="25.6" spread="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of diabetes</title>
          <description>Number of years since diagnosis</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.4" spread="5.4"/>
                    <measurement group_id="B2" value="7.5" spread="5.3"/>
                    <measurement group_id="B3" value="7.2" spread="5.2"/>
                    <measurement group_id="B4" value="7.8" spread="6.1"/>
                    <measurement group_id="B5" value="7.5" spread="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>m</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.63" spread="0.09"/>
                    <measurement group_id="B2" value="1.63" spread="0.09"/>
                    <measurement group_id="B3" value="1.62" spread="0.08"/>
                    <measurement group_id="B4" value="1.64" spread="0.09"/>
                    <measurement group_id="B5" value="1.63" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68.6" spread="11.6"/>
                    <measurement group_id="B2" value="67.4" spread="11.3"/>
                    <measurement group_id="B3" value="68.2" spread="11.9"/>
                    <measurement group_id="B4" value="68.2" spread="11.9"/>
                    <measurement group_id="B5" value="68.1" spread="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Glycosylated Haemoglobin A1c (HbA1c)</title>
        <description>Percentage point change in Glycosylated Haemoglobin A1c (HbA1c) from baseline (week 0) to 16 weeks (end of treatment).</description>
        <time_frame>week 0, week 16</time_frame>
        <population>The Full Analysis Set (FAS) using LOCF (Last Observation Carried Forward) is all randomised subjects who had been exposed to at least one dose of the study products.</population>
        <group_list>
          <group group_id="O1">
            <title>Lira 0.6 + Met</title>
            <description>Liraglutide 0.6 mg once daily + metformin 1.5-2.0 g daily + glimepiride placebo</description>
          </group>
          <group group_id="O2">
            <title>Lira 1.2 + Met</title>
            <description>Liraglutide 1.2 mg once daily + metformin 1.5-2.0 g daily + glimepiride placebo</description>
          </group>
          <group group_id="O3">
            <title>Lira 1.8 + Met</title>
            <description>Liraglutide 1.8 mg once daily + metformin 1.5-2.0 g daily + glimepiride placebo</description>
          </group>
          <group group_id="O4">
            <title>Glim + Met</title>
            <description>Glimepiride 4.0 mg + metformin 1.5-2.0 g daily + liraglutide placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Glycosylated Haemoglobin A1c (HbA1c)</title>
          <description>Percentage point change in Glycosylated Haemoglobin A1c (HbA1c) from baseline (week 0) to 16 weeks (end of treatment).</description>
          <population>The Full Analysis Set (FAS) using LOCF (Last Observation Carried Forward) is all randomised subjects who had been exposed to at least one dose of the study products.</population>
          <units>percentage point of total HbA1c</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="226"/>
                <count group_id="O2" value="222"/>
                <count group_id="O3" value="221"/>
                <count group_id="O4" value="230"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" spread="1.04"/>
                    <measurement group_id="O2" value="-1.3" spread="1.09"/>
                    <measurement group_id="O3" value="-1.4" spread="1.23"/>
                    <measurement group_id="O4" value="-1.3" spread="0.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Based on standard normal theory, the sample size needed in order to be able to show that lira + met is non-inferior to glim + met when using a 1:1 randomisation and a non-inferiority criteria of 0.4% with a power of at least 85%, is tabulated below using different SD of HbA1c.
Assuming a drop out rate of 25%, the total number of subjects to be randomised is 896 (224 for each dose of the liraglutide + metformin group and 224 subjects in metformin+glimepiride treatment group) with a SD of 1.2%.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority is concluded if the two-sided upper limit of the 95% confidence interval for treatment difference in mean change in HbA1c between lira 1.8mg + met and glim + met is below 0.4%.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Non-inferiority; &lt;.0001. In order to protect the overall Type I error rate when testing for non-inferiority of the three doses of lira + met to glim + met, the comparisons will be invoked sequentially for descending doses of liraglutide.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment, country and previous treatment as fixed effects and baseline value as a covariate.</method_desc>
            <param_type>Estimated treatment difference, LS Mean</param_type>
            <param_value>-0.06</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.23</ci_lower_limit>
            <ci_upper_limit>0.11</ci_upper_limit>
            <estimate_desc>The p-values correspond to one-sided hypotheses of either superiority or non-inferiority. Statistical significance on a 2.5% level.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Based on standard normal theory, the sample size needed in order to be able to show that lira + met is non-inferior to glim + met when using a 1:1 randomisation and a non-inferiority criteria of 0.4% with a power of at least 85%, is tabulated below using different SD of HbA1c.
Assuming a drop out rate of 25%, the total number of subjects to be randomised is 896 (224 for each dose of the liraglutide + metformin group and 224 subjects in metformin+glimepiride treatment group) with a SD of 1.2%.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority is concluded if the two-sided upper limit of the 95% confidence interval for treatment difference in mean change in HbA1c between lira 1.2mg + met and glim + met is below 0.4%.</non_inferiority_desc>
            <p_value>&lt;.0001</p_value>
            <p_value_desc>In order to protect the overall Type I error rate when testing for non-inferiority of the three doses of lira + met to glim + met, the comparisons will be invoked sequentially for descending doses of liraglutide.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment, country and previous treatment as fixed effects and baseline value as a covariate.</method_desc>
            <param_type>Estimated treatment difference, LS Mean</param_type>
            <param_value>0.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.14</ci_lower_limit>
            <ci_upper_limit>0.20</ci_upper_limit>
            <estimate_desc>The p-values correspond to one-sided hypotheses of either superiority or non-inferiority. Statistical significance on a 2.5% level.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Based on standard normal theory, the sample size needed in order to be able to show that lira + met is non-inferior to glim + met when using a 1:1 randomisation and a non-inferiority criteria of 0.4% with a power of at least 85%, is tabulated below using different SD of HbA1c.
Assuming a drop out rate of 25%, the total number of subjects to be randomised is 896 (224 for each dose of the liraglutide + metformin group and 224 subjects in metformin+glimepiride treatment group) with a SD of 1.2%.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority is concluded if the two-sided upper limit of the 95% confidence interval for treatment difference in mean change in HbA1c between lira 0.6mg + met and glim + met is below 0.4%.</non_inferiority_desc>
            <p_value>0.0421</p_value>
            <p_value_desc>In order to protect the overall Type I error rate when testing for non-inferiority of the three doses of lira + met to glim + met, the comparisons will be invoked sequentially for descending doses of liraglutide.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment, country and previous treatment as fixed effects and baseline value as a covariate.</method_desc>
            <param_type>Estimated treatment difference, LS Mean</param_type>
            <param_value>0.25</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.08</ci_lower_limit>
            <ci_upper_limit>0.42</ci_upper_limit>
            <estimate_desc>The p-values correspond to one-sided hypotheses of either superiority or non-inferiority.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Body Weight</title>
        <description>Change in body weight from baseline (week 0) to 16 weeks (end of treatment)</description>
        <time_frame>week 0, week 16</time_frame>
        <population>The Full Analysis Set (FAS) using LOCF (Last Observation Carried Forward) is all randomised subjects who had been exposed to at least one dose of the study products.</population>
        <group_list>
          <group group_id="O1">
            <title>Lira 0.6 + Met</title>
            <description>Liraglutide 0.6 mg once daily + metformin 1.5-2.0 g daily + glimepiride placebo</description>
          </group>
          <group group_id="O2">
            <title>Lira 1.2 + Met</title>
            <description>Liraglutide 1.2 mg once daily + metformin 1.5-2.0 g daily + glimepiride placebo</description>
          </group>
          <group group_id="O3">
            <title>Lira 1.8 + Met</title>
            <description>Liraglutide 1.8 mg once daily + metformin 1.5-2.0 g daily + glimepiride placebo</description>
          </group>
          <group group_id="O4">
            <title>Glim + Met</title>
            <description>Glimepiride 4.0 mg + metformin 1.5-2.0 g daily + liraglutide placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Body Weight</title>
          <description>Change in body weight from baseline (week 0) to 16 weeks (end of treatment)</description>
          <population>The Full Analysis Set (FAS) using LOCF (Last Observation Carried Forward) is all randomised subjects who had been exposed to at least one dose of the study products.</population>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="227"/>
                <count group_id="O2" value="225"/>
                <count group_id="O3" value="224"/>
                <count group_id="O4" value="231"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.8" spread="2.2"/>
                    <measurement group_id="O2" value="-2.3" spread="2.4"/>
                    <measurement group_id="O3" value="-2.4" spread="2.6"/>
                    <measurement group_id="O4" value="0.1" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Self-measured Fasting Plasma Glucose</title>
        <description>Change in self-measured fasting plasma glucose from baseline (week 0) to 16 weeks (end of treatment). Self-measurement of plasma glucose was performed using a glucose meter and subjects were instructed to record self-measured plasma glucose values into a diary.</description>
        <time_frame>week 0, week 16</time_frame>
        <population>The Full Analysis Set (FAS) using LOCF (Last Observation Carried Forward) is all randomised subjects who had been exposed to at least one dose of the study products.</population>
        <group_list>
          <group group_id="O1">
            <title>Lira 0.6 + Met</title>
            <description>Liraglutide 0.6 mg once daily + metformin 1.5-2.0 g daily + glimepiride placebo</description>
          </group>
          <group group_id="O2">
            <title>Lira 1.2 + Met</title>
            <description>Liraglutide 1.2 mg once daily + metformin 1.5-2.0 g daily + glimepiride placebo</description>
          </group>
          <group group_id="O3">
            <title>Lira 1.8 + Met</title>
            <description>Liraglutide 1.8 mg once daily + metformin 1.5-2.0 g daily + glimepiride placebo</description>
          </group>
          <group group_id="O4">
            <title>Glim + Met</title>
            <description>Glimepiride 4.0 mg + metformin 1.5-2.0 g daily + liraglutide placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Self-measured Fasting Plasma Glucose</title>
          <description>Change in self-measured fasting plasma glucose from baseline (week 0) to 16 weeks (end of treatment). Self-measurement of plasma glucose was performed using a glucose meter and subjects were instructed to record self-measured plasma glucose values into a diary.</description>
          <population>The Full Analysis Set (FAS) using LOCF (Last Observation Carried Forward) is all randomised subjects who had been exposed to at least one dose of the study products.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="224"/>
                <count group_id="O2" value="226"/>
                <count group_id="O3" value="222"/>
                <count group_id="O4" value="229"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.83" spread="2.66"/>
                    <measurement group_id="O2" value="-1.96" spread="2.35"/>
                    <measurement group_id="O3" value="-2.28" spread="2.94"/>
                    <measurement group_id="O4" value="-2.13" spread="2.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>7-point Self-measured Plasma Glucose Profiles</title>
        <description>Summary of 7-Point Profiles of Self-Measured Plasma Glucose by Treatment, Week and Time. The 7 time points for self-measurements for all treatment groups were: Before each meal (breakfast, lunch and dinner), at 90 min after start of each meal (breakfast, lunch and dinner) and at bedtime, measured over 16 weeks of treatment (at week 0, 8, 12 and 16).</description>
        <time_frame>week 0, 8, 12 and 16</time_frame>
        <population>The Full Analysis Set (FAS) using LOCF (Last Observation Carried Forward) is all randomised subjects who had been exposed to at least one dose of the study products.</population>
        <group_list>
          <group group_id="O1">
            <title>Lira 0.6 + Met</title>
            <description>Liraglutide 0.6 mg once daily + metformin 1.5-2.0 g daily + glimepiride placebo</description>
          </group>
          <group group_id="O2">
            <title>Lira 1.2 + Met</title>
            <description>Liraglutide 1.2 mg once daily + metformin 1.5-2.0 g daily + glimepiride placebo</description>
          </group>
          <group group_id="O3">
            <title>Lira 1.8 + Met</title>
            <description>Liraglutide 1.8 mg once daily + metformin 1.5-2.0 g daily + glimepiride placebo</description>
          </group>
          <group group_id="O4">
            <title>Glim + Met</title>
            <description>Glimepiride 4.0 mg + metformin 1.5-2.0 g daily + liraglutide placebo</description>
          </group>
        </group_list>
        <measure>
          <title>7-point Self-measured Plasma Glucose Profiles</title>
          <description>Summary of 7-Point Profiles of Self-Measured Plasma Glucose by Treatment, Week and Time. The 7 time points for self-measurements for all treatment groups were: Before each meal (breakfast, lunch and dinner), at 90 min after start of each meal (breakfast, lunch and dinner) and at bedtime, measured over 16 weeks of treatment (at week 0, 8, 12 and 16).</description>
          <population>The Full Analysis Set (FAS) using LOCF (Last Observation Carried Forward) is all randomised subjects who had been exposed to at least one dose of the study products.</population>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="231"/>
                <count group_id="O2" value="233"/>
                <count group_id="O3" value="233"/>
                <count group_id="O4" value="231"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0 - Before breakfast</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="168.2" spread="43.5"/>
                    <measurement group_id="O2" value="167.5" spread="42.5"/>
                    <measurement group_id="O3" value="168.8" spread="40.4"/>
                    <measurement group_id="O4" value="163.8" spread="41.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 0 - 90 minutes after breakfast</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="245.9" spread="71.6"/>
                    <measurement group_id="O2" value="248.0" spread="70.0"/>
                    <measurement group_id="O3" value="245.4" spread="63.8"/>
                    <measurement group_id="O4" value="238.5" spread="62.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 0 - Before lunch</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="178.5" spread="62.7"/>
                    <measurement group_id="O2" value="180.5" spread="63.5"/>
                    <measurement group_id="O3" value="176.9" spread="56.8"/>
                    <measurement group_id="O4" value="175.8" spread="61.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 0 - 90 minutes after lunch</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="234.2" spread="68.7"/>
                    <measurement group_id="O2" value="232.3" spread="67.0"/>
                    <measurement group_id="O3" value="234.4" spread="64.2"/>
                    <measurement group_id="O4" value="227.6" spread="67.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 0 - Before dinner</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="194.8" spread="63.0"/>
                    <measurement group_id="O2" value="184.8" spread="65.0"/>
                    <measurement group_id="O3" value="190.9" spread="61.7"/>
                    <measurement group_id="O4" value="180.2" spread="59.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 0 - 90 minutes after dinner</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="239.6" spread="65.3"/>
                    <measurement group_id="O2" value="239.6" spread="71.3"/>
                    <measurement group_id="O3" value="244.0" spread="69.8"/>
                    <measurement group_id="O4" value="231.6" spread="60.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 0 - Bedtime</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="205.7" spread="69.6"/>
                    <measurement group_id="O2" value="208.1" spread="67.5"/>
                    <measurement group_id="O3" value="219.3" spread="71.7"/>
                    <measurement group_id="O4" value="202.7" spread="66.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 - Before breakfast</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="137.0" spread="31.2"/>
                    <measurement group_id="O2" value="130.4" spread="28.0"/>
                    <measurement group_id="O3" value="133.7" spread="28.4"/>
                    <measurement group_id="O4" value="130.1" spread="31.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 - 90 minutes after breakfast</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="198.5" spread="55.8"/>
                    <measurement group_id="O2" value="190.1" spread="50.8"/>
                    <measurement group_id="O3" value="178.5" spread="48.2"/>
                    <measurement group_id="O4" value="201.2" spread="54.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 - Before lunch</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="144.8" spread="45.2"/>
                    <measurement group_id="O2" value="136.5" spread="41.8"/>
                    <measurement group_id="O3" value="138.0" spread="37.8"/>
                    <measurement group_id="O4" value="132.6" spread="46.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 - 90 minutes after lunch</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="187.2" spread="48.7"/>
                    <measurement group_id="O2" value="176.9" spread="49.5"/>
                    <measurement group_id="O3" value="177.9" spread="48.4"/>
                    <measurement group_id="O4" value="184.3" spread="54.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 - Before dinner</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="159.1" spread="47.5"/>
                    <measurement group_id="O2" value="147.8" spread="40.1"/>
                    <measurement group_id="O3" value="144.2" spread="40.6"/>
                    <measurement group_id="O4" value="143.3" spread="47.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 - 90 minutes after dinner</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="193.7" spread="53.2"/>
                    <measurement group_id="O2" value="187.1" spread="49.3"/>
                    <measurement group_id="O3" value="183.3" spread="53.9"/>
                    <measurement group_id="O4" value="190.2" spread="51.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 - Bedtime</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="169.1" spread="51.5"/>
                    <measurement group_id="O2" value="161.6" spread="47.1"/>
                    <measurement group_id="O3" value="155.8" spread="45.6"/>
                    <measurement group_id="O4" value="163.6" spread="50.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 - Before breakfast</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="137.8" spread="33.6"/>
                    <measurement group_id="O2" value="130.2" spread="25.0"/>
                    <measurement group_id="O3" value="130.2" spread="26.8"/>
                    <measurement group_id="O4" value="128.5" spread="29.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 - 90 minutes after breakfast</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="197.5" spread="54.2"/>
                    <measurement group_id="O2" value="185.7" spread="49.4"/>
                    <measurement group_id="O3" value="178.6" spread="51.6"/>
                    <measurement group_id="O4" value="200.8" spread="57.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 - Before lunch</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="141.8" spread="48.3"/>
                    <measurement group_id="O2" value="135.6" spread="40.3"/>
                    <measurement group_id="O3" value="134.1" spread="40.3"/>
                    <measurement group_id="O4" value="129.3" spread="47.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 - 90 minutes after lunch</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="183.7" spread="50.0"/>
                    <measurement group_id="O2" value="174.7" spread="46.2"/>
                    <measurement group_id="O3" value="173.7" spread="53.1"/>
                    <measurement group_id="O4" value="185.3" spread="52.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 - Before dinner</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="156.4" spread="44.8"/>
                    <measurement group_id="O2" value="143.4" spread="36.1"/>
                    <measurement group_id="O3" value="144.5" spread="43.0"/>
                    <measurement group_id="O4" value="144.2" spread="49.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 - 90 minutes after dinner</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="197.2" spread="51.8"/>
                    <measurement group_id="O2" value="185.7" spread="47.1"/>
                    <measurement group_id="O3" value="183.5" spread="51.7"/>
                    <measurement group_id="O4" value="188.5" spread="50.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 - Bedtime</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="168.2" spread="52.1"/>
                    <measurement group_id="O2" value="158.9" spread="45.3"/>
                    <measurement group_id="O3" value="158.9" spread="47.0"/>
                    <measurement group_id="O4" value="159.9" spread="47.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 - Before breakfast</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="137.3" spread="31.2"/>
                    <measurement group_id="O2" value="132.9" spread="26.4"/>
                    <measurement group_id="O3" value="128.6" spread="26.1"/>
                    <measurement group_id="O4" value="131.0" spread="35.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 - 90 minutes after breakfast</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="195.6" spread="57.1"/>
                    <measurement group_id="O2" value="188.7" spread="51.6"/>
                    <measurement group_id="O3" value="177.6" spread="51.6"/>
                    <measurement group_id="O4" value="195.1" spread="57.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 - Before lunch</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="140.5" spread="41.3"/>
                    <measurement group_id="O2" value="137.0" spread="40.3"/>
                    <measurement group_id="O3" value="137.8" spread="40.8"/>
                    <measurement group_id="O4" value="128.8" spread="45.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 - 90 minutes after lunch</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="185.8" spread="44.4"/>
                    <measurement group_id="O2" value="181.4" spread="46.7"/>
                    <measurement group_id="O3" value="173.2" spread="50.7"/>
                    <measurement group_id="O4" value="182.2" spread="51.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 - Before dinner</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="151.5" spread="38.5"/>
                    <measurement group_id="O2" value="148.4" spread="39.8"/>
                    <measurement group_id="O3" value="140.9" spread="38.8"/>
                    <measurement group_id="O4" value="144.9" spread="45.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 - 90 minutes after dinner</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="195.0" spread="52.2"/>
                    <measurement group_id="O2" value="183.3" spread="46.2"/>
                    <measurement group_id="O3" value="173.2" spread="48.3"/>
                    <measurement group_id="O4" value="192.6" spread="53.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 - Bedtime</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="166.4" spread="50.6"/>
                    <measurement group_id="O2" value="159.8" spread="44.7"/>
                    <measurement group_id="O3" value="151.6" spread="40.3"/>
                    <measurement group_id="O4" value="157.7" spread="47.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Beta-cell Function</title>
        <description>Change in beta cell function from baseline (week 0) to 16 weeks (end of treatment). Beta-cell function was derived from fasting plasma glucose (FPG) and fasting insulin concentrations using the homeostasic model assessment (HOMA) method which uses the assumption that normal-weight normal subjects aged under 35 years have a 100% beta-cell function (HOMA-B).
Beta-cell function: HOMA-B (%) = 20∙fasting insulin[uU/mL] divided by (FPG mmol/L]‑3.5).</description>
        <time_frame>week 0, week 16</time_frame>
        <population>The Full Analysis Set (FAS) using LOCF (Last Observation Carried Forward) is all randomised subjects who had been exposed to at least one dose of the study products.</population>
        <group_list>
          <group group_id="O1">
            <title>Lira 0.6 + Met</title>
            <description>Liraglutide 0.6 mg once daily + metformin 1.5-2.0 g daily + glimepiride placebo</description>
          </group>
          <group group_id="O2">
            <title>Lira 1.2 + Met</title>
            <description>Liraglutide 1.2 mg once daily + metformin 1.5-2.0 g daily + glimepiride placebo</description>
          </group>
          <group group_id="O3">
            <title>Lira 1.8 + Met</title>
            <description>Liraglutide 1.8 mg once daily + metformin 1.5-2.0 g daily + glimepiride placebo</description>
          </group>
          <group group_id="O4">
            <title>Glim + Met</title>
            <description>Glimepiride 4.0 mg + metformin 1.5-2.0 g daily + liraglutide placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Beta-cell Function</title>
          <description>Change in beta cell function from baseline (week 0) to 16 weeks (end of treatment). Beta-cell function was derived from fasting plasma glucose (FPG) and fasting insulin concentrations using the homeostasic model assessment (HOMA) method which uses the assumption that normal-weight normal subjects aged under 35 years have a 100% beta-cell function (HOMA-B).
Beta-cell function: HOMA-B (%) = 20∙fasting insulin[uU/mL] divided by (FPG mmol/L]‑3.5).</description>
          <population>The Full Analysis Set (FAS) using LOCF (Last Observation Carried Forward) is all randomised subjects who had been exposed to at least one dose of the study products.</population>
          <units>percentage point (%point)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="216"/>
                <count group_id="O2" value="216"/>
                <count group_id="O3" value="213"/>
                <count group_id="O4" value="222"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.3" spread="94.6"/>
                    <measurement group_id="O2" value="17.8" spread="30.4"/>
                    <measurement group_id="O3" value="21.7" spread="78.5"/>
                    <measurement group_id="O4" value="21.8" spread="43.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Fasting Lipid Profile</title>
        <description>Change in fasting lipid profiles from baseline (week 0) to 16 weeks (end of treatment). Fasting lipid profiles is based on:
Total Cholesterol (TC)
Low-density Lipoprotein-cholesterol (LDL-C)
Very Low-density Lipoprotein-cholesterol (VLDL-C)
High-density Lipoprotein-cholesterol (HDL-C)
Triglyceride (TG)
Free Fatty Acid (FFA)</description>
        <time_frame>week 0, week 16</time_frame>
        <population>The Full Analysis Set (FAS) using LOCF (Last Observation Carried Forward) is all randomised subjects who had been exposed to at least one dose of the study products.</population>
        <group_list>
          <group group_id="O1">
            <title>Lira 0.6 + Met</title>
            <description>Liraglutide 0.6 mg once daily + metformin 1.5-2.0 g daily + glimepiride placebo</description>
          </group>
          <group group_id="O2">
            <title>Lira 1.2 + Met</title>
            <description>Liraglutide 1.2 mg once daily + metformin 1.5-2.0 g daily + glimepiride placebo</description>
          </group>
          <group group_id="O3">
            <title>Lira 1.8 + Met</title>
            <description>Liraglutide 1.8 mg once daily + metformin 1.5-2.0 g daily + glimepiride placebo</description>
          </group>
          <group group_id="O4">
            <title>Glim + Met</title>
            <description>Glimepiride 4.0 mg + metformin 1.5-2.0 g daily + liraglutide placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Fasting Lipid Profile</title>
          <description>Change in fasting lipid profiles from baseline (week 0) to 16 weeks (end of treatment). Fasting lipid profiles is based on:
Total Cholesterol (TC)
Low-density Lipoprotein-cholesterol (LDL-C)
Very Low-density Lipoprotein-cholesterol (VLDL-C)
High-density Lipoprotein-cholesterol (HDL-C)
Triglyceride (TG)
Free Fatty Acid (FFA)</description>
          <population>The Full Analysis Set (FAS) using LOCF (Last Observation Carried Forward) is all randomised subjects who had been exposed to at least one dose of the study products.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="231"/>
                <count group_id="O2" value="233"/>
                <count group_id="O3" value="233"/>
                <count group_id="O4" value="231"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change in TC (Absolute), N=221, 216, 216, 228</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06" spread="0.74"/>
                    <measurement group_id="O2" value="-0.01" spread="0.77"/>
                    <measurement group_id="O3" value="-0.03" spread="0.73"/>
                    <measurement group_id="O4" value="0.02" spread="0.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in LDL-C (Absolute), N=221, 216, 216, 228</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06" spread="0.61"/>
                    <measurement group_id="O2" value="-0.03" spread="0.64"/>
                    <measurement group_id="O3" value="0.00" spread="0.58"/>
                    <measurement group_id="O4" value="0.04" spread="0.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in VLDL-C (Absolute), N=213, 210, 207, 220</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="0.35"/>
                    <measurement group_id="O2" value="0.05" spread="0.40"/>
                    <measurement group_id="O3" value="0.01" spread="0.35"/>
                    <measurement group_id="O4" value="0.05" spread="0.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in HDL-C (Absolute), N=217, 212, 212, 220</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.02" spread="0.19"/>
                    <measurement group_id="O2" value="-0.05" spread="0.34"/>
                    <measurement group_id="O3" value="-0.05" spread="0.15"/>
                    <measurement group_id="O4" value="-0.01" spread="0.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in TG (Absolute), N=220, 212, 213, 226</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.08" spread="0.96"/>
                    <measurement group_id="O2" value="-0.06" spread="1.13"/>
                    <measurement group_id="O3" value="-0.22" spread="1.57"/>
                    <measurement group_id="O4" value="-0.07" spread="1.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in FFA (Absolute), N=218, 214, 216, 227</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.03" spread="0.28"/>
                    <measurement group_id="O2" value="-0.04" spread="0.28"/>
                    <measurement group_id="O3" value="-0.10" spread="0.28"/>
                    <measurement group_id="O4" value="-0.02" spread="0.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Fasting Lipid Profile, APO-B</title>
        <description>Change in fasting lipid profiles based on apolipoprotein B (Apo-B) from baseline (week 0) to 16 weeks (end of treatment).</description>
        <time_frame>week 0, week 16</time_frame>
        <population>The Full Analysis Set (FAS) using LOCF (Last Observation Carried Forward) is all randomised subjects who had been exposed to at least one dose of the study products.</population>
        <group_list>
          <group group_id="O1">
            <title>Lira 0.6 + Met</title>
            <description>Liraglutide 0.6 mg once daily + metformin 1.5-2.0 g daily + glimepiride placebo</description>
          </group>
          <group group_id="O2">
            <title>Lira 1.2 + Met</title>
            <description>Liraglutide 1.2 mg once daily + metformin 1.5-2.0 g daily + glimepiride placebo</description>
          </group>
          <group group_id="O3">
            <title>Lira 1.8 + Met</title>
            <description>Liraglutide 1.8 mg once daily + metformin 1.5-2.0 g daily + glimepiride placebo</description>
          </group>
          <group group_id="O4">
            <title>Glim + Met</title>
            <description>Glimepiride 4.0 mg + metformin 1.5-2.0 g daily + liraglutide placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Fasting Lipid Profile, APO-B</title>
          <description>Change in fasting lipid profiles based on apolipoprotein B (Apo-B) from baseline (week 0) to 16 weeks (end of treatment).</description>
          <population>The Full Analysis Set (FAS) using LOCF (Last Observation Carried Forward) is all randomised subjects who had been exposed to at least one dose of the study products.</population>
          <units>g/L</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="221"/>
                <count group_id="O2" value="216"/>
                <count group_id="O3" value="216"/>
                <count group_id="O4" value="228"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" spread="0.17"/>
                    <measurement group_id="O2" value="0.00" spread="0.18"/>
                    <measurement group_id="O3" value="-0.00" spread="0.16"/>
                    <measurement group_id="O4" value="0.01" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hypoglycaemic Episodes</title>
        <description>Total number of hypoglycaemic episodes over 16 weeks of treatment occurring from baseline (week 0) to end of treatment (week 16). Hypoglycaemic episodes were defined as major, minor, or symptoms only. Major if the subject was unable to treat her/himself. Minor if subject was able to treat her/himself and plasma glucose was below 3.1 mmol/L. Symptoms only if subject was able to treat her/himself and with no plasma glucose measurement or plasma glucose higher than or equal to 3.1 mmol/L.</description>
        <time_frame>weeks 0-16</time_frame>
        <population>Safety Analysis Set is all randomised subjects who have been exposed to at least one dose of study products.</population>
        <group_list>
          <group group_id="O1">
            <title>Lira 0.6 + Met</title>
            <description>Liraglutide 0.6 mg once daily + metformin 1.5-2.0 g daily + glimepiride placebo</description>
          </group>
          <group group_id="O2">
            <title>Lira 1.2 + Met</title>
            <description>Liraglutide 1.2 mg once daily + metformin 1.5-2.0 g daily + glimepiride placebo</description>
          </group>
          <group group_id="O3">
            <title>Lira 1.8 + Met</title>
            <description>Liraglutide 1.8 mg once daily + metformin 1.5-2.0 g daily + glimepiride placebo</description>
          </group>
          <group group_id="O4">
            <title>Glim + Met</title>
            <description>Glimepiride 4.0 mg + metformin 1.5-2.0 g daily + liraglutide placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Hypoglycaemic Episodes</title>
          <description>Total number of hypoglycaemic episodes over 16 weeks of treatment occurring from baseline (week 0) to end of treatment (week 16). Hypoglycaemic episodes were defined as major, minor, or symptoms only. Major if the subject was unable to treat her/himself. Minor if subject was able to treat her/himself and plasma glucose was below 3.1 mmol/L. Symptoms only if subject was able to treat her/himself and with no plasma glucose measurement or plasma glucose higher than or equal to 3.1 mmol/L.</description>
          <population>Safety Analysis Set is all randomised subjects who have been exposed to at least one dose of study products.</population>
          <units>episodes</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="231"/>
                <count group_id="O2" value="233"/>
                <count group_id="O3" value="233"/>
                <count group_id="O4" value="231"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Major</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Minor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Symptoms only</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The adverse events were collected over a time span of 16 weeks.</time_frame>
      <desc>The safety analysis set is all who had been exposed to at least one dose of the study products.</desc>
      <group_list>
        <group group_id="E1">
          <title>Lira 0.6 + Met</title>
          <description>Liraglutide 0.6 mg once daily + metformin 1.5-2.0 g daily + glimepiride placebo</description>
        </group>
        <group group_id="E2">
          <title>Lira 1.2 + Met</title>
          <description>Liraglutide 1.2 mg once daily + metformin 1.5-2.0 g daily + glimepiride placebo</description>
        </group>
        <group group_id="E3">
          <title>Lira 1.8 + Met</title>
          <description>Liraglutide 1.8 mg once daily + metformin 1.5-2.0 g daily + glimepiride placebo</description>
        </group>
        <group group_id="E4">
          <title>Glim + Met</title>
          <description>Glimepiride 4.0 mg + metformin 1.5-2.0 g daily + liraglutide placebo</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="233"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="233"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="231"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Adams-Stokes syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="233"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="233"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="231"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="233"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="231"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="231"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="231"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="231"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="233"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="231"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="233"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="231"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="233"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="233"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="231"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="231"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="233"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="231"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cryptogenic cirrhosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="231"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="231"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Epiglottitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="233"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="233"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="231"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="231"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="233"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="233"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="233"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Skull fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="233"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="231"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="233"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="231"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Benign hydatidiform mole</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="233"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Lung squamous cell carcinoma stage unspecified</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="233"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="231"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Brain injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="233"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Cerebellar infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="233"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Cerebellar haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="233"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Cubital tunnel syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="231"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="67" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="98" subjects_at_risk="233"/>
                <counts group_id="E3" subjects_affected="113" subjects_at_risk="233"/>
                <counts group_id="E4" subjects_affected="30" subjects_at_risk="231"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="29" subjects_affected="28" subjects_at_risk="231"/>
                <counts group_id="E2" events="43" subjects_affected="36" subjects_at_risk="233"/>
                <counts group_id="E3" events="50" subjects_affected="40" subjects_at_risk="233"/>
                <counts group_id="E4" events="25" subjects_affected="20" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="33" subjects_affected="29" subjects_at_risk="231"/>
                <counts group_id="E2" events="36" subjects_affected="32" subjects_at_risk="233"/>
                <counts group_id="E3" events="40" subjects_affected="38" subjects_at_risk="233"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="18" subjects_affected="17" subjects_at_risk="231"/>
                <counts group_id="E2" events="22" subjects_affected="22" subjects_at_risk="233"/>
                <counts group_id="E3" events="35" subjects_affected="33" subjects_at_risk="233"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="231"/>
                <counts group_id="E2" events="17" subjects_affected="16" subjects_at_risk="233"/>
                <counts group_id="E3" events="13" subjects_affected="12" subjects_at_risk="233"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="231"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="231"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="233"/>
                <counts group_id="E3" events="14" subjects_affected="12" subjects_at_risk="233"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="231"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="231"/>
                <counts group_id="E2" events="33" subjects_affected="33" subjects_at_risk="233"/>
                <counts group_id="E3" events="35" subjects_affected="35" subjects_at_risk="233"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="231"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="233"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="233"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="231"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Novo Nordisk maintains the right to be informed of any investigator plans for publication and to review any scientific paper, presentation, communication and other information concerning the investigation described in this protocol. Any such communication must be submitted in writing to the Novo Nordisk trial manager prior to submission for comments. Comments will be given within four weeks from receipt of the planned communication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Public Access to Clinical Trials</name_or_title>
      <organization>Novo Nordisk A/S</organization>
      <email>clinicaltrials@novonordisk.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

